Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US-2015133446-A1 · May 14, 2015 · US
PAR4 inhibitor therapy for patients with PAR4 polymorphism
US9789087B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9789087-B2 |
| Application number | US-201615226425-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 2, 2016 |
| Priority date | Aug 3, 2015 |
| Publication date | Oct 17, 2017 |
| Grant date | Oct 17, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are methods for determining whether a PAR4 inhibitor should be administered to a human subject, the methods comprising administering a PAR4 inhibitor to a subject determined to have a “G” allele for a single-nucleotide polymorphism (SNP) at rs773902, and not administering a PAR4 inhibitor to a subject determined to have an “A” allele for the SNP at rs773902. A genotyping assay can be used to determine the SNP.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of preventing or treating thrombosis in a human subject in need thereof, the method comprising administering a therapeutically effective amount of a PAR4 inhibitor to a human subject determined to have a “G” allele for a single-nucleotide polymorphism (SNP) at rs773902. 2. The method of claim 1 wherein the method of preventing or treating thrombosis in a human subject further comprises, wherein (a) the human subject is being administered a PAR1 inhibitor and (b) has a “G” allele for a single-nucleotide polymorphism (SNP) at rs773902; the method comprising (a) stopping administration of the PAR1 inhibitor and (b) administering a therapeutically effective amount of a PAR4 inhibitor. 3. The method of claim 1 , wherein the PAR4 inhibitor is selected from the group consisting of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3), trans-cinnamoyl-YPGKF-amide, P4pal-i1, and palmitoyl-SGRRYGHALR-amide (P4pal-10). 4. The method of claim 1 , wherein the thrombosis is associated with coronary artery disease, stroke, vascular thrombosis, arterial thrombosis, atherothrombosis, deep vein thrombosis, peripheral vascular disease, peripheral arterial disease, or an inflammatory disease. 5. The method of claim 1 , further comprising testing a sample from the human subject to determine the genotype of the SNP at rs773902. 6. The method of claim 5 , wherein the sample is a blood sample, a urine sample, a buccal sample, a saliva sample, or a hair sample. 7. The method of claim 1 , further comprising administering a therapeutically effective amount of a P2Y12 inhibitor to the subject selected from the group consist of: clopidogrel, prasugrel, ticagrelor, or cangrelor, a salt thereof, or a combination thereof.
Assignees
Inventors
Classifications
Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title
Polymorphic or mutational markers · CPC title
- A61K31/416Primary
condensed with carbocyclic ring systems, e.g. indazole · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
by carboxylic acids, e.g. acetylsalicylic acid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9789087B2 cover?
- Disclosed herein are methods for determining whether a PAR4 inhibitor should be administered to a human subject, the methods comprising administering a PAR4 inhibitor to a subject determined to have a “G” allele for a single-nucleotide polymorphism (SNP) at rs773902, and not administering a PAR4 inhibitor to a subject determined to have an “A” allele for the SNP at rs773902. A genotyping assay …
- Who is the assignee on this patent?
- Univ Jefferson
- What technology area does this patent fall under?
- Primary CPC classification A61K31/416. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).